Cambridge-based Black Diamond Therapeutics, a clinical-stage company specializing in precision oncology medicine, is dedicated to discovering and developing therapies for patients suffering from genetically-defined cancers. The firm's promising lead product candidate, BDTX-1535, specifically inhibits oncogenic mutations and is currently undergoing Phase 1 clinical trials. In addition to this, their BDTX-4933 is a highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, designed to penetrate the blood-brain barrier, and is expected to initiate Phase 1 clinical trials shortly. Formerly known as ASET Therapeutics, Inc., the company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and has its headquarters in Cambridge, Massachusetts.
Black Diamond Therapeutics, Inc.'s ticker is BDTX
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 11-50 employees working at Black Diamond Therapeutics, Inc.
It is https://www.blackdiamondtherapeutics.com/
Black Diamond Therapeutics, Inc. is in the Healthcare sector
Black Diamond Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Black Diamond Therapeutics, Inc.'s industry peers: